Effectiveness and Safety of Sofosbuvir-Based Regimens for Chronic HCV Genotype 3 Infection: Results of the HCV-TARGET Study

Background. Sofosbuvir (SOF) is active against all hepatitis C virus (HCV) genotypes, and SOF-based therapies lead to high rates of sustained virologic response (SVR). However, genotype 3 (GT3) HCV remains a challenge with lower SVR rates reported, particularly in patients with cirrhosis. This study...

Full description

Saved in:

Bibliographic Details
Published in:	Clin Infect Dis
Main Authors:	Feld, Jordan J., Maan, Raoel, Zeuzem, Stefan, Kuo, Alexander, Nelson, David R., Di Bisceglie, Adrian M., Manns, Michael P., Sherman, Ken, Frazier, Lynn M., Sterling, Richard, Mailliard, Mark, Schmidt, Monica, Akushevich, Lucy, Vainorius, Monika, Fried, Michael W.
Format:	Artigo
Language:	Inglês
Published:	Oxford University Press 2016
Subjects:	Articles and Commentaries
Online Access:	https://ncbi.nlm.nih.gov/pmc/articles/PMC4996139/ https://ncbi.nlm.nih.gov/pubmed/27325691 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/cid/ciw387
Tags:	Add Tag No Tags, Be the first to tag this record!

Effectiveness and Safety of Sofosbuvir-Based Regimens for Chronic HCV Genotype 3 Infection: Results of the HCV-TARGET Study

Similar Items